Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: 135(7)
Published: March 31, 2025
Non-small cell lung cancer (NSCLC), the most common type of cancer, remains a leading cause cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have emerged as promising therapy for NSCLC but only benefit subset patients. In this issue JCI, Jiao et al. revealed that acetyl-CoA acetyltransferase 1 (ACAT1) limited efficacy ICIs in by impeding tertiary lymphoid structures (TLS) tumor microenvironment (TME). Targeting ACAT1 cells reduced mitochondrial hypersuccinylation and oxidative stress, enhancing TLS abundance improving preclinical murine models NSCLC.
Language: Английский